Here, we present real-world data on a large cohort of advanced NSCLC patients harboring BRAF mutations from five Italian Institutions in the attempt to describe clinical features and survival outcomes, with particular attention given to potential differences between BRAF V600E mutated and non-V600E mutated subgroups. This evidence concerns the gene BRAF and non-small cell lung carcinoma.